| 28165004 |
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S,
Zhang, H,
Chai, Y,
Song, H,
Tong, Z,
Wang, Q,
Qi, J,
Wong, G,
Zhu, X,
Liu, WJ,
Gao, S,
Wang, Z,
Shi, Y,
Yang, F,
Gao, GF,
Yan, J
|
Nat Commun |
2017 |
| 29863979 |
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Migden, MR,
Rischin, D,
Schmults, CD,
Guminski, A,
Hauschild, A,
Lewis, KD,
Chung, CH,
Hernandez-Aya, L,
Lim, AM,
Chang, ALS,
Rabinowits, G,
Thai, AA,
Dunn, LA,
Hughes, BGM,
Khushalani, NI,
Modi, B,
Schadendorf, D,
Gao, B,
Seebach, F,
Li, S,
Li, J,
Mathias, M,
Booth, J,
Mohan, K,
Stankevich, E,
Babiker, HM,
Brana, I,
Gil-Martin, M,
Homsi, J,
Johnson, ML,
Moreno, V,
Niu, J,
Owonikoko, TK,
Papadopoulos, KP,
Yancopoulos, GD,
Lowy, I,
Fury, MG
|
N. Engl. J. Med. |
2018 |
| 28265006 |
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Burova, E,
Hermann, A,
Waite, J,
Potocky, T,
Lai, V,
Hong, S,
Liu, M,
Allbritton, O,
Woodruff, A,
Wu, Q,
D'Orvilliers, A,
Garnova, E,
Rafique, A,
Poueymirou, W,
Martin, J,
Huang, T,
Skokos, D,
Kantrowitz, J,
Popke, J,
Mohrs, M,
MacDonald, D,
Ioffe, E,
Olson, W,
Lowy, I,
Murphy, A,
Thurston, G
|
Mol. Cancer Ther. |
2017 |